Skye Bioscience, Inc.
SKYE
$0.72
$0.068.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.44M | -12.75M | -17.62M | -11.10M | -9.75M |
| Total Depreciation and Amortization | 180.00K | 178.90K | 187.10K | 177.40K | 175.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00 |
| Total Other Non-Cash Items | 1.44M | 1.82M | 1.94M | 2.20M | 2.27M |
| Change in Net Operating Assets | 3.06M | -2.61M | 4.75M | -461.40K | -869.40K |
| Cash from Operations | -9.77M | -13.36M | -10.75M | -9.19M | -8.17M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -6.30K | -50.00K |
| Sale of Property, Plant, and Equipment | 180.00K | 91.40K | 89.40K | -- | 140.40K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.98M | 7.88M | -11.94M | -12.80M | -- |
| Cash from Investing | -2.80M | 7.97M | -11.86M | -12.81M | 90.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 6.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 11.40K | 0.00 | 18.20K | -- | -6.43M |
| Cash from Financing | 11.40K | 0.00 | 18.20K | -- | 5.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.56M | -5.40M | -22.58M | -21.99M | -8.08M |